Abstract
Background
Little information is available regarding the mechanism of cyclophosphamide (CP)-induced renal damage. Therefore, this study examined whether carnitine deficiency constitutes a risk factor in and should be viewed as a mechanism during development of CP-induced nephrotoxicity and explored whether carnitine supplementation, using propionyl-l-carnitine (PLC), could offer protection against this toxicity.
Methods
Experimental rats were assigned to one of six groups; the first three groups were injected intraperitoneally with normal saline, PLC (250 mg/kg/day) or d-carnitine (250 mg/kg/day) + Mildronate (200 mg/kg/day), respectively, for 10 successive days. The 4th, 5th and 6th groups received the same doses of normal saline, PLC or d-carnitine + Mildronate, respectively, for 5 successive days before and after a single dose of CP (200 mg/kg).
Results
CP significantly increased serum creatinine, blood urea nitrogen (BUN), intramitochondrial acetyl-coenzyme A (CoA) and thiobarbituric acid reactive substances, significantly decreased total carnitine, intramitochondrial CoA-SH, adenosine triphosphate (ATP) and ATP/adenosine diphosphate (ADP) and reduced glutathione in kidney tissues. In carnitine-depleted rats, CP resulted in dramatic increase in serum nephrotoxicity indices and acetyl-CoA and induced progressive reduction in total carnitine, CoA-SH and ATP as well as severe histopathological lesions in kidney tissues. Interestingly, PLC completely reversed the biochemical and histopathological changes induced by CP to normal values.
Conclusions
Oxidative stress is not involved in CP-induced renal injury in this model. Carnitine deficiency and energy starvation constitute risk factors in and should be viewed as a mechanism during CP-induced nephrotoxicity. PLC prevents development of CP-induced nephrotoxicity by increasing intracellular carnitine content, intramitochondrial CoA-SH/acetyl-CoA ratio and energy production.
Similar content being viewed by others
References
Preiss R, Baumann F. Cyclophosphamide and related anticancer drugs. J Chromatogr B Biomed Sci Appl. 2001;764:173–92.
Murphy SB, Bowman WP, Abromowitch M, Mirro J, Ochs J, Rivera G, et al. Results of treatment of advanced-stage Burkitt’s lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol. 1986;4:1732–9.
Luo XO, Mo Y, Ke ZY, Xu L, Jiang XY, Zhang TT, et al. High-dose chemotherapy without stem cell transplantation for refractory childhood systemic lupus erythematosus. Chemotherapy. 2008;54:331–5.
Nissim I, Weinberg JM. Glycine attenuates maleate or ifosfamide induced Fanconi syndrome in rats. Kidney Int. 1996;49:684–95.
Badary OA. Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice. J Ethnopharmacol. 1999;67:135–42.
Nissim I, Horyn O, Daikhin Y, Nissim I, Luhovyy B, Phillips BC, et al. Ifosfamide-induced nephrotoxicity: mechanism and prevention. Cancer Res. 2006;66:7824–31.
Yaseen Z, Michoudet C, Baverel G, Dubourg L. Mechanisms of the ifosfamide-induced inhibition of endocytosis in the rat proximal kidney tubule. Arch Toxicol. 2008;82:607–14.
Mizushima Y, Sassa K, Hamazaki T, Fujishita T, Oosaki R, Kobayashi M. Diuretic response to cyclophosphamide in rats bearing a matrix metalloproteinase-9-producing tumour. BJC. 1998;78:1030–4.
Stankiewicz A, Skrzydlewska E. Protection against cyclophosphamide-induced renal oxidative stress by amifostine: the role of antioxidative mechanisms. Toxicol Mech Methods. 2003;13:301–8.
Abraham P, Indirani K, Sugumar E. Effect of cyclophosphamide treatment on selected lysosomal enzymes in the kidney of rats. Exp Toxicol Pathol. 2007;59:143–9.
Abraham P, Sugumar E. Enhanced PON1 activity in the kidneys of cyclophosphamide treated rats may play a protective role as an antioxidant against cyclophosphamide induced oxidative stress. Arch Toxicol. 2008;82:237–8.
Abraham P, Rabi S. Nitrosative stress, protein tyrosine nitration, PARP activation and NAD depletion in the kidneys of rats after single dose of cyclophosphamide. Clin Exp Nephrol. 2009;13:281–7.
Ayhanci A, Günes S, Sahinturk V, Appak S, Uyar R, Cengiz M, et al. Seleno l-methionine acts on cyclophosphamide-induced kidney toxicity. Biol Trace Elem Res. 2009;136(2):171–9.
Fatani AG, Darweesh AQ, Rizwan L, Aleisa AM, Al-Shabanah OA, Sayed-Ahmed MM. Carnitine deficiency aggravates cyclophosphamide-induced cardiotoxicity in rats. Chemotherapy. 2010;56:71–81.
Kerner J, Hoppel C. Fatty acid import into mitochondria. Biochim Biophys Acta. 2000;1486:1–17.
Mancinelli A, Longo A, Shanahan K, Evans AM. Disposition of l-carnitine and acetyl-l-carnitine in the isolated perfused rat kidney. J Pharmacol Exp Ther. 1995;274:1122–8.
Paulson DJ, Shug AL. Tissue specific depletion of l-carnitine in rat heart and skeletal muscle by d-carnitine. Life Sci. 1981;28:2931–8.
Whitmer JT. l-carnitine treatment improves cardiac performance and restores high energy phosphate pools in cardiomyopathic Syrian hamster. Circ Res. 1987;61:396–408.
Tsoko M, Beau-Seigneur F, Greste J, Niot I, Demarquoy J, Biochot J, et al. Enhancement of activities relative to fatty acid oxidation in the liver of rats depleted of l-carnitine by d-carnitine and a γ-butyrobetaine hydroxylase inhibitor. Biochem Pharmacol. 1995;49:1403–10.
Kuwajima M, Harashima H, Hayashi M, Ise S, Sei M, Lu K, et al. Pharmacokinetic analysis of the cardioprotective effect of 3-(2, 2, 2-trimethylhydrazinium) propionate in mice: inhibition of carnitine transport in kidney. J Pharmacol Exp Ther. 1999;289:93–102.
Spaniol M, Brooks H, Auer L, Zimmermann A, Solioz M, Stieger B, et al. Development and characterization of an animal model of carnitine deficiency. Eur J Biochem. 2001;268:1876–87.
Peschechera A, Scalibastri M, Russo F, Giarrizzo MG, Carminati P, Giannessi F, et al. Carnitine depletion in rat pups from mothers given mildronate: a model of carnitine deficiency in late fetal and neonatal life. Life Sci. 2005;77:3078–91.
Tobacco A, Meiattini F, Moda E, Tarii P. Simplified enzymic/colorimetric serum urea nitrogen determination. Clin Chem. 1979;25:336–7.
Fabiny DL, Ertingshausen G. Automated reaction-rate method for determination of serum creatinine with the Centrifichem. Clin Chem. 1971;17:696–700.
Ellman GL. Tissue sulfahydryl groups. Arch Biochem Biophys. 1959;82:70–7.
Ohkawa H, Ohish N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid. Anal Biochem. 1979;95:351–8.
Botker HE, Kimose M, Helligso P, Nielsen TT. Analytical evaluation of high-energy phosphate determination by high performance liquid chromatography in myocardial tissue. J Mol Cell Cardiol. 1994;26:41–8.
Prieto JA, Andrade F, Aldmiz-Echevarra L, Sanjurjo P. Determination of free and total carnitine in plasma by an enzymatic reaction and spectrophotometric quantitation spectrophotometric determination of carnitine. Clin Biochem. 2006;39:1022–7.
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.
Lysiak W, Lilly K, DiLisa F, Toth PP, Bieber LL. Quantitation of the effect of l-carnitine on the levels of acid-soluble short-chain acyl-CoA and CoASH in rat heart and liver mitochondria. J Biol Chem. 1988;263:1151–6.
Senthilkumar S, Devaki T, Manohar BM, Babu MS. Effect of squalene on cyclophosphamide-induced toxicity. Clin Chim Acta. 2006;364:335–42.
Ahmed S, Thomas H, Golper TA, Wolfson M, Kurtin P, Katz LA, et al. Multi-center trial of l-carnitine in maintenance hemodialysis patients II. Clinical and biochemical effects. Kidney Int. 1990;38:912–8.
Marthaler NP, Visarius T, Küpfer A, Lauterburg BH. Increased urinary losses of carnitine during ifosfamide chemotherapy. Cancer Chemother Pharmacol. 1999;44:170–2.
Heuberger W, Berardi S, Jacky E, Pey P, Krahenbuhl S. Increased urinary excretion of carnitine in patients treated with cisplatin. Eur J Clin Pharmacol. 1998;54:503–8.
Arafa HM. Carnitine deficiency aggravates carboplatin nephropathy through deterioration of energy status, oxidant/anti-oxidant balance, and inflammatory endocoids. Toxicol. 2008;254:51–60.
Sayed-Ahmed MM, Eissa MA, Kenawy SA, Mostafa N, Calvani M, Osman AM. Progression of cisplatin-induced nephrotoxicity in a carnitine-depleted rat model. Chemotherapy. 2004;50:162–70.
Al-Shabanah OA, Aleisa AM, Al-Yahya AA, Al-Rejaie SS, Bakheet SA, Fatani AG, et al. Increased urinary losses of carnitine and decreased intramitochondrial coenzyme A in gentamicin-induced acute renal failure in rats. Nephrol Dial Transplant. 2010;25:69–76.
Steiber A, Kerner J, Hoppel CL. Carnitine: a nutritional, biosynthetic, and functional perspective. Mol Aspects Med. 2004;25:455–73.
Abdel-aleem S, Nada MA, Sayed-Ahmed MM, Hendrickson SC, St Louis J, Walthall HP, et al. Regulation of fatty acid oxidation by acetyl-CoA generated from glucose utilization in isolated myocytes. J Mol Cell Cardiol. 1996;28:825–33.
Dayanandan A, Kumar P, Panneerselvam C. Protective role of l-carnitine on liver and heart lipid peroxidation in atherosclerotic rats. J Nutr Biochem. 2001;12:254–7.
Sayed-Ahmed MM, Khattab MM, Gad MZ, Mostafa N. l-carnitine prevents the progression of atherosclerotic lesions in hypercholesterolaemic rabbits. Pharmacol Res. 2001;44:235–42.
Sayed-Ahmed MM, Mansour HH, Gharib OA, Hafez HF. Acetyl-l-carnitine modulates bleomycin-induced oxidative stress and energy depletion in lung tissues. J Egypt Natl Cancer Inst. 2004;16:237–43.
Al-Majed AA, Sayed-Ahmed MM, Al-Yahya AA, Aleisa AM, Al-Rejaie SS, Al-Shabanah OA. Propionyl-l-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model. Pharmacol Res. 2006;53:278–86.
Al-Rejaie SS, Aleisa AM, Al-Yahya AA, Bakheet SA, Alsheikh A, Fatani AG, et al. Progression of diethylnitrosamine-induced hepatic carcinogenesis in carnitine-depleted rats. World J Gastroenterol. 2009;15:1373–80.
Acknowledgments
Author of this study are grateful to Dr. Zaven Orfalin, Sigma-Tau Pharmaceuticals, Pomezia, Italy, for providing PLC, d-carnitine and Mildronate. The present work was supported by an operating grant from the Research Center, College of Pharmacy, King Saud University (CPRC080144).
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Sayed-Ahmed, M.M. Progression of cyclophosphamide-induced acute renal metabolic damage in carnitine-depleted rat model. Clin Exp Nephrol 14, 418–426 (2010). https://doi.org/10.1007/s10157-010-0321-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-010-0321-0